Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA9 | Q16790 | 6/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 3/20 | 0.38 |
| ▸ | ELF3 | P78545 | 1/20 | 0.37 |
| ▸ | MED23 | Q9ULK4 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147612 | 0.92 | CA1 (0.55) | CA12CA1CA2CA9PTGER3 | |
| SCHEMBL878574 | 0.90 | CA1 (0.53) | CA12CA1CA2CA9PTGER3 | |
| SCHEMBL10148185 | 0.84 | HTRA2 (0.35) | — | |
| SCHEMBL878698 | 0.81 | ALB (0.47) | CA12CA1CA2CA9 | |
| SCHEMBL878334 | 0.79 | ESR1 (0.34) | BTK | |
| SCHEMBL860830 | 0.71 | CA12 (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL12185033 | 0.70 | CA1 (0.54) | CA12CA1CA2CA9PTGER3 | |
| SCHEMBL861474 | 0.70 | CA12 (0.56) | CA12CA1CA2CA9FKBP1A | |
| SCHEMBL13955226 | 0.69 | CA1 (0.54) | CA12CA1CA2CA9PTGER3 | |
| SCHEMBL13290324 | 0.69 | CA1 (0.54) | CA12CA1CA2CA9PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | CA12 77/4885CA1 305/4885CA2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.